OBJECTIVES: Cost Utility Analysis of Sacral Neuromodulation (SNM) vs. botulin toxin type A (BoNTA) in Overactive Bladder (OAB) treatment in Colombia METHODS: Through the adaptation of an HTA Consulting economic model and after data transferability analysis, a cost-utility analysis of SNM vs. BoNTA 100UI in the treatment of OAB in Colombia was done. The model was constructed as a Discrete Event Simulation. The effectiveness data of SNM and BoNTA, defined as more than 50% improvement in urinary parameters, was based on studies identified in systematic review Jaros 2013 conducted in Polish settings. Based in systematic search for health-related quality of life data, one health state for treatment success and one for treatment failure were defined, as well as disutility related to treatment. The costs data was obtain from the Colombian Public Reimbursement Tariff Manual and from urologist medical group specialized in OAB treatment, which also reviewed and adjusted the frequency of resources use. A 10 years horizon and a 3% discount rate were used. Deterministic and probabilistic sensitive analyses were done. RESULTS: The treatment with SNM obtained 5.67 QALYs vs. 5.38 QALYs obtained with BoNTA with 0.28 incremental QALYs. The total costs were US$27,828 vs. US$28,906, with minus US$1,077 incremental Dollars. Because SNM was more effective and less costly, dominates to BoNTA, meaning that is cost-saving respect to this. 49.1% of the simulations in the Probabilistic Sensitivity analysis were in the NE quadrant, more effective and more costly, and 50.9% in the SE quadrant, more effective and less costly than BoNTA, and 100% under the threshold of 3 Colombian GDP Per Capita. CONCLUSIONS: SNM has a higher effectiveness than BoNTA in terms of Quality of Life at a lower cost and compared to BoNTA is a cost-saving therapy for the treatment of OAB in Colombia.